In the News

Alzheimer’s Research and Treatment Center

Dr. David Watson of ARTC is one of the primary author’s of this article on Lecanemab and Alzheimer’s Disease.

The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer’s disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer’s disease.